Pay in 4 interest-free payments of $6.49 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
Grimm M, Han J, Weaver C, Griffin P, Schulteis CT, Dong H, Malloy J (2013) Efficacy, safety, and tolerability of exenatide once weekly in patients with type 2 diabetes mellitus: an integrated analysis of the DURATION trials
Other forms of primary liver disease can potentiate cirrhosis in patients with hemochromatosis with homozygous or heterozygous mutations.
Wu Shugeng, Feed Research Institute (CAAS), China Updates Copyright 2022 Li, Wen, Yu, Li, Wang, Qiao, Song and Huang
Yao S, Yuan Y, Zhang H, Meng X, Jin L, Yang J, et al
Differences in total reduced GSH were: 74.5294.8 mol/L versus 34.5334.7 mol/L for the GSH group and the placebo group, respectively ( p =0.67 between groups)
Research ArticleInflammationMetabolism Open Access | 10.1172/jci.insight.154314 1 Department of Biochemistry, Microbiology and Immunology, Faculty of Medicine, University of Ottawa, Ontario, Canada
US$ 20.96
US$ 21.25
US$ 22.03
US$ 27.24
US$ 28.12
US$ 26.90
US$ 24.01
